Major Swedish research university strong in neurodegeneration, cancer biology, vaccine science, marine research, and European open science infrastructure.
The University of Gothenburg is a major Swedish research university with deep strengths in biomedical sciences — particularly neurodegenerative disease, cancer biology, and vaccine development — alongside significant marine and environmental science programs. Their H2020 portfolio reveals a university that both trains the next generation of researchers through extensive Marie Skłodowska-Curie fellowships and conducts frontline research in areas from Alzheimer's biomarkers to ocean health. They also serve as a key node in European research infrastructure networks, contributing to ESFRI roadmap facilities and open science initiatives.
Multiple projects target neurodegeneration, microglia, Alzheimer's biomarkers, and synaptic dysfunction (SyDAD, MIROCALS, TRAIN-ERS, and others referencing neurodegeneration in keywords).
Projects span antioxidant roles in cancer (RAC), ALK activation (ALKATRAS), protein complexes inducing cell death (EPIC), and endocrine-disrupting chemicals linked to cancer risk (EDC-MixRisk).
Sustained involvement in Ebola vaccine trials (VSV-EBOVAC, VSV-EBOPLUS at EUR 1.76M) and systems vaccinology research including transcriptomics and immunogenicity signatures.
Projects in ocean health (SeaChange), marine snow biophysics (BIPHA), and recent keywords showing environmental DNA and oceanography as growing focus areas.
Recent keyword clusters around ESFRI, FAIR data principles, open science, and research infrastructures indicate growing engagement in building shared European scientific infrastructure.
Recent keywords feature intersectionality, governance, refugees, and risk communication, with projects like PARTISPACE examining youth participation and societal challenges.
In the early H2020 period (2015–2018), Gothenburg concentrated heavily on molecular and cellular biomedicine — neurodegeneration, microglia, inflammation, Alzheimer's disease, and cancer — alongside marine science and climate-related environmental work. From 2019 onward, the university broadened significantly toward open science infrastructure (FAIR data, ESFRI), social sciences (intersectionality, governance, risk communication), and environmental genomics (environmental DNA, oceanography). This shift suggests the university is positioning itself not just as a producer of biomedical research, but as a builder of the infrastructure and frameworks through which European science operates.
Gothenburg is evolving from a biomedical research performer into a dual-role institution that combines disease-focused research with leadership in open science infrastructure and data governance — making them an increasingly strategic partner for large-scale, multi-domain consortia.
With 65 coordinator roles out of 170 projects (38%), Gothenburg frequently leads projects — especially MSCA fellowships — while also joining large consortia as a specialist partner in health and environment. Their network of 1,296 unique partners across 67 countries marks them as a genuine hub institution: they build broad, diverse consortia rather than relying on a fixed circle of collaborators. This makes them both accessible to new partners and experienced at managing international teams.
With 1,296 unique consortium partners spanning 67 countries, Gothenburg maintains one of the most extensive collaboration networks among Swedish universities — reaching well beyond Europe into global partnerships. Their strongest connections are in Western and Northern Europe, but the breadth suggests active engagement with partners across all EU member states and associated countries.
Gothenburg combines world-class biomedical research (particularly in neurodegeneration and cancer) with strong marine science capabilities — a rare dual strength rooted in Sweden's coastal research tradition. Unlike many large universities that stay within their disciplinary silos, they actively bridge domains: biomarkers meet environmental DNA, clinical trials meet open science infrastructure. Their heavy MSCA portfolio also means they attract and train international researchers at scale, making them a talent pipeline as well as a research partner.
